Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study

Plain-language guide to PMID 39791502 (2025): placebo-controlled randomized controlled trial study of Abaloparatide in 12 men, osteoporosis and bone density.

Key Facts

PMID: 39791502
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Year: 2025
Study type: Randomized Controlled Trial
Authors: Eastell R et al. (9 authors)
DOI: 10.1093/jbmr/zjaf003

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Abaloparatide in the context of osteoporosis and bone density, published as a randomized controlled trial.

The uncoupling index (UI), a measure of the balance between markers of bone formation (PINP) and bone resorption (CTX), with positive UI favoring bone formation, was calculated.

Results in men were compared to 12-mo results for women from the ACTIVE study using the z score test after Fisher's Z transformation.

Who Took Part

The study group was 12 men.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The men were allocated by chance, so the Abaloparatide group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Abaloparatide group a baseline to be compared against.

What Was Measured

The uncoupling index (UI), a measure of the balance between markers of bone formation (PINP) and bone resorption (CTX), with positive UI favoring bone formation, was calculated.

Results in men were compared to 12-mo results for women from the ACTIVE study using the z score test after Fisher's Z transformation.

PubMed files the paper under topics including Bone Density, Biomarkers, Osteoporosis, Bone Remodeling, Parathyroid Hormone-Related Protein, Procollagen and Peptide Fragments.

Author keywords: CTX, PINP, abaloparatide, bone turnover markers and uncoupling index.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Abaloparatide in 12 men in people with osteoporosis and bone density.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2025 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Abaloparatide compound page, Osteoporosis and bone density research.

Our Notes on the Compound

Abaloparatide: A synthetic parathyroid hormone-related peptide (PTHrP) analog used as a bone-building (anabolic) osteoporosis medicine.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.